# Human Longevity

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/human-longevity

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.humanlongevity.com
- Total disclosed funding: $633M
- Latest round: Series B (Mar 13, 2023)
- Investors on record: 10

## About

Founded in 2013 by founder J. Craig Venter and based in California, US, Human Longevity, Inc. provides a clinical research platform that compiles and analyzes genotypic and phenotypic data to understand and generate insights that will help to accelerate ways to discover and prevent risks and signals of diseases. In August 2024, Human Longevity, Inc. raised USD 21.5 million in Series B funding. The Series B funding values Human Longevity, Inc. at USD 173.26 million post-money.


Human Longevity, Inc. v offers genome sequencing to analyze an individual’s genetic makeup. This information helps in assessing genetic risk factors and guiding personalized health recommendations. The company conducts detailed health evaluations that include diagnostic tests to identify potential health issues and develop personalized health management plans. The diagnostic tests include coronary calcium scoring, advanced blood tests, echocardiograms, electrocardiograms, exercise stress tests, and insulin sensitivity testing. These tests help in assessing cardiovascular health, metabolic function, and other health parameters. Additionally, the firm uses wearable technology to track daily health metrics, such as glucose levels and sleep patterns. This continuous monitoring helps refine health recommendations and interventions.

## Funding rounds

- Series B, Mar 13, 2023, $11M — Emerging Technology Partners, TVM Capital Healthcare, Panacea Venture
- Series C, Jun 14, 2019, $20M — Emerging Technology Partners
- Series B, Feb 16, 2017, $203M — Draper Fisher Jurvetson, Bristol-Myers Squibb Company, Illumina Ventures, GE Ventures
- Series B, Mar 26, 2015, $320M — Draper Fisher Jurvetson, BB Retail Capital, Genting Berhad, Bristol-Myers Squibb Company, Awaken Capital, GE Ventures
- Series A, Mar 20, 2014, $80M — Draper Fisher Jurvetson, Illumina Ventures

## Investors

- Draper Fisher Jurvetson (https://capitalatlas.ai/funds/draper-fisher-jurvetson) — Series A, Series B
- Illumina Ventures (https://capitalatlas.ai/funds/illumina-ventures) — Series A, Series B
- BB Retail Capital — Series B
- Genting Berhad — Series B
- Bristol-Myers Squibb Company — Series B
- Awaken Capital (https://capitalatlas.ai/funds/awaken-capital) — Series B
- GE Ventures — Series B
- Emerging Technology Partners (https://capitalatlas.ai/funds/emerging-technology-partners) — Series C, Series B
- TVM Capital Healthcare (https://capitalatlas.ai/funds/tvm-capital-healthcare) — Series B
- Panacea Venture (https://capitalatlas.ai/funds/panacea-venture) — Series B